Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Abstract In the aftermath of the COVID-19 pandemic, the evolution of the SARS-CoV-2 into a seasonal pathogen along with the emergence of new variants, underscores the need for dynamic and adaptable responses, emphasizing the importance of sustained vaccination strategies. This observer-blind, double...

Full description

Bibliographic Details
Main Authors: Lawrence Reiter, Johann Greffrath, Bian Zidel, Mario Ostrowski, Jennifer Gommerman, Shabir A. Madhi, Richard Tran, Natalia Martin-Orozco, Rajesh Krishnan Gopalakrishna Panicker, Curtis Cooper, Aleksandra Pastrak
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-55320-1

Internet

https://doi.org/10.1038/s41598-024-55320-1

Similar Items